510 results on '"Taub R"'
Search Results
2. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors
3. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference
4. Diabetes and acute aortic dissection: insights from the International Registry of Acute Aortic Dissection
5. Molecular Configuration and Biological Activity of Substances Resembling Acetylcholine
6. P1521In a 36-week placebo-controlled phase 2 trial in patients with non-alcoholic steatohepatitis (NASH), treatment with MGL-3196 (resmetirom) significantly reduces atherogenic lipoprotein particles
7. P5387LDL cholesterol, apolipoprotein B, lipoprotein(a), apolipoprotein CIII and triglyceride lowering by MGL-3196, a thyroid hormone beta selective agonist, in a 12 week study in HeFH patients
8. MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study
9. Acute Myeloblastic Leukemia-Associated Antigens: Detection and Clinical Importance
10. Allograft Reaction
11. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease
12. “Could I be pregnant?” Questions about emergency contraception among English- and Spanish-speaking users of the Web site not-2-late.com
13. GS-009 - MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study
14. Induction of tolerance to skin homografts with a methylhydrazine derivative. Synergism with antilymphocytic serum and morphologic responses of the lymphoid system
15. Acute Myeloblastic Leukemia-Associated Antigens: Detection and Clinical Importance
16. Immunotherapy of Human Cancer1
17. Biological Effects of Heterologous Antilymphocyte Serum1
18. Repeated ambulatory intrapleural chemotherapy for malignant pleural mesothelioma.
19. A phase I dose-escalation study of azacitidine in combination with temozolomide in patients with soft tissue sarcomas.
20. Use of laser capture microdissection to derive poor prognosis gene expression signatures of epithelial abdominal malignant mesothelioma
21. A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM)
22. Influence of microscopic malignant peritoneal mesothelioma on posttreatment survival
23. Socio-demographic factors in a pediatric chronic pain clinic: the role of minority status in pain and health outcomes
24. Serum and intracavitary soluble mesothelin-related peptide (SMRP) levels in pleural and peritoneal malignant mesothelioma
25. Operative morbidity and mortality in 54 consecutive patients undergoing operative cytoreduction and intraperitoneal chemotherapy for peritoneal mesothelioma
26. Phase II trial of oxaliplatin and gemcitabine in patients with malignant pleural or peritoneal mesothelioma
27. Lung-sparing intrapleural chemotherapy plus P32 radiation for pleural mesothelioma
28. 18FDG-PET in the management of malignant peritoneal mesothelioma: A retrospective review of 145 scans in 37 patients
29. The use of in-vitro drug resistance levels as a predictor of outcome in soft tissue sarcoma
30. Biological control systems - A critical review and evaluation
31. 111 Multimodality regional therapy for peritoneal mesothelioma
32. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors
33. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors
34. Phase II trial of oxaliplatin and gemcitabine in patients with malignant pleural or peritoneal mesothelioma
35. Can Learning a Frequency Discrimination Task Occur Without Discrimination?
36. P-620 An update of pemetrexed (P) plus gemcitabine (G) asfront-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial
37. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for malignant peritoneal mesothelioma (MPM)
38. Phase II study of temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma
39. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for malignant peritoneal mesothelioma (MPM)
40. An update of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial
41. A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM)
42. Phase I/II study of docetaxel (D), gemcitabine (G), Carboplatin (C) in poor prognosis and previously treated patients (pts) with urothelial carcinoma (UTC)
43. Effects of Flecainide in Patients With New SCN5A Mutation
44. The Corporeal Meaning of Time: Phenomenology and Literature: Lévinas, Reader of Proust
45. From the Self to Oneself: Subject and Interiority in Spinoza
46. INITIATION OF EARLY SIGNAL TRANSDUCTION PATHWAYS IN THE LIVER FOLLOWING COLD ISCHEMIA AND REPERFUSION INJURY
47. INITIATION OF SIGNAL TRANSDUCER AND ACTIVATORS OF TRANSCRIPTION (STATs) FOLLOWING ISCHEMIA/REPERFUSION INJURY
48. CCAAT enhancer- binding protein beta is required for normal hepatocyte proliferation in mice after partial hepatectomy.
49. Treatment with interleukin-6 reduces liver damage and apoptotic hepatocyte death and enhances recovery in acute toxic injury
50. HRS/SRp40-mediated inclusion of the fibronectin EIIIB exon, a possible cause of increased EIIIB expression in proliferating liver
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.